logo
logo

Jnana Therapeutics Appoints George Vratsanos, M.D., As

Jul 19, 2023•about 2 years ago

Position

Chief Medical Officer

Company

Jnana Therapeutics Inc.

George Vratsanos
BostonBiotechnology

Description

BOSTON, July 19, 2023 -- Jnana Therapeutics , a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced the appointment of George Vratsanos, M.D., F.A.C.R., to chief medical officer and head of research and development. Dr. Vratsanos brings over 20 years of experience in roles spanning translational medicine, late-stage therapeutics development, and medical affairs

Company Information

Company

Jnana Therapeutics Inc.

Location

6 Tide Street

Boston, Massachusetts, United States

About

Jnana Therapeutics is a clinical-stage biotechnology company leveraging its next-generation chemoproteomics RAPID platform to discover medicines for highly validated, challenging-to-drug targets to treat diseases with high unmet need. Jnana is focused on developing first- and best-in-class therapies to treat a wide range of diseases, including rare diseases, immune-mediated diseases and cancer. Jnana’s wholly owned lead program is a potential first-in-class oral approach, targeting an allosteric site on the phenylalanine transporter SLC6A19, for the treatment of phenylketonuria (PKU), a rare genetic metabolic disease. Located in Boston, Jnana brings together scientific leaders in small molecule drug discovery and development, a highly experienced management team and the backing of leading life science investors Bain Capital Life Sciences, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures and AbbVie Ventures.

Related People

Sign in to view contact details

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months